These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38898657)

  • 41. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
    Lipton RB; Munjal S; Alam A; Buse DC; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
    Headache; 2018 Oct; 58(9):1408-1426. PubMed ID: 30341895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.
    Hepp Z; Dodick DW; Varon SF; Chia J; Matthew N; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2017 Apr; 37(5):470-485. PubMed ID: 27837173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.
    Gilligan AM; Foster SA; Sainski-Nguyen A; Sedgley R; Smith D; Morrow P
    J Occup Environ Med; 2018 Dec; 60(12):1120-1127. PubMed ID: 30199470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
    Dodick DW; Reed ML; Lee L; Balkaran BL; Umashankar K; Parikh M; Gandhi P; Buse DC
    Headache; 2024 Apr; 64(4):361-373. PubMed ID: 38523435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes.
    Yeaw J; Lee WC; Aagren M; Christensen T
    J Manag Care Pharm; 2012; 18(1):21-32. PubMed ID: 22235952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    Patient Prefer Adherence; 2022; 16():821-839. PubMed ID: 35378732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of care and costs of switching oral antipsychotic medications in patients with schizophrenia initiating monotherapy treatment: A US claims analysis.
    Fee R; Webb N; Dick L; White J; Essoi B; Walker V; Zacker C
    J Manag Care Spec Pharm; 2024 Jun; 30(6):560-571. PubMed ID: 38591754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine.
    Shewale AR; Brandenburg JA; Burslem K; Lipton RB; Doshi JA
    Cephalalgia; 2024 Feb; 44(2):3331024241235139. PubMed ID: 38410849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adherence to oral migraine-preventive medications among patients with chronic migraine.
    Hepp Z; Dodick DW; Varon SF; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2015 May; 35(6):478-88. PubMed ID: 25164920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M; Benner J; Neumann P; Menzin J
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
    Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
    Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
    Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The medical costs of migraine and comorbid anxiety and depression.
    Pesa J; Lage MJ
    Headache; 2004 Jun; 44(6):562-70. PubMed ID: 15186300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.